MET and gastrointestinal stromal tumor: Taken together, our data indicate the prospective use of the multi-kinase inhibitors of c-MET (crizotinib, cabozantinib, etc.)and FGFR (ponatinib, dovitinib, etc.)for GIST patients with secondary resistance to IM due to this type of RTK switch.